pharmaphorum
AUGUST 3, 2020
The US drugmaker is testing the antibody – called LY-CoV555 and developed in collaboration with Canadian biotech AbCellera – in a phase 3 trial to see if it can prevent the spread of the coronavirus among residents and staff in US nursing homes. The fleet will be sent out in response to outbreaks of the virus at long-term care units.
The Pharma Data
DECEMBER 14, 2020
ICU nurse Sandra Lindsay, with Long Island Jewish Medical Center in Queens, New York, received the Pfizer-BioNTech COVID-19 vaccine. Both vaccines have demonstrated about 94-95% efficacy in clinical trials. pcruciatti / Shutterstock. Yesterday was a historic day as the first person in the U.S., They have since recovered.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 2, 2020
Still, the temperature requirement could dictate who will be vaccinated first in Britain: While nursing home residents were supposed to be the top priority under an advisory committee’s plans, efforts to limit transportation of the vaccine may mean that National Health Service staff will receive the shots first, the Times reported.
The Pharma Data
JANUARY 24, 2021
With a presidential inauguration and a federal holiday, it wasn’t an enormously busy week for clinical trial news, but there was a fair amount, nonetheless. It inked a deal with the National Institute of Allergy and Infectious Diseases (NIAID) to launch a Phase I trial. Read on to see. COVID-19-Related.
The Pharma Data
JANUARY 26, 2021
In the trial, the safety profile of bamlanivimab and etesevimab together was consistent with observations from other Phase 1, Phase 2 and Phase 3 trials evaluating these antibodies. Serious adverse events were reported at a similar frequency in the bamlanivimab and etesevimab together and placebo groups.
The Pharma Data
DECEMBER 19, 2020
National Institute of Allergy and Infectious Diseases. Moderna’s vaccine was shown to be 94 percent effective in its large clinical trial; Pfizer’s vaccine was 95 percent effective. “I believe that’s possible.” billion, the Post reported.
The Pharma Data
DECEMBER 18, 2020
National Institute of Allergy and Infectious Diseases. Moderna’s vaccine was shown to be 94 percent effective in its large clinical trial, while Pfizer’s vaccine was 95 percent effective. billion, the Post reported. A vast majority of Americans will not be eligible for vaccinations until the spring or later.
Expert insights. Personalized for you.
59 
Let's personalize your content